295 related articles for article (PubMed ID: 28786987)
1. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
5. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
6. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study).
Yoon SJ; Choi SH; Na HR; Park KW; Kim EJ; Han HJ; Lee JH; Shim YS; Na DL
Geriatr Gerontol Int; 2017 Mar; 17(3):494-499. PubMed ID: 27111084
[TBL] [Abstract][Full Text] [Related]
7. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
8. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
9. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
Yatawara C; Zailan FZ; Chua EV; Lim LLH; Silva E; Wang JS; Ng A; Ng KP; Kandiah N
Clin Interv Aging; 2021; 16():301-309. PubMed ID: 33642856
[TBL] [Abstract][Full Text] [Related]
11. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
[TBL] [Abstract][Full Text] [Related]
14. Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
Jia J; Ji Y; Feng T; Ye Q; Peng D; Kuang W; Ning Y; Liang Z; Fan D; Wei W; Li Y; Xiao S
J Alzheimers Dis; 2019; 72(4):1313-1322. PubMed ID: 31744005
[TBL] [Abstract][Full Text] [Related]
15. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Velting DM
Alzheimer Dis Assoc Disord; 2015; 29(2):110-6. PubMed ID: 25437301
[TBL] [Abstract][Full Text] [Related]
16. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
18. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.
Alva G; Cummings JL; Galvin JE; Meng X; Velting DM
Int J Clin Pract; 2015 May; 69(5):518-30. PubMed ID: 25684069
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
[TBL] [Abstract][Full Text] [Related]
20. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
